This review compared bypass grafting (CABG) with percutaneous transluminal coronary angioplasty (PTCA) in patients with coronary artery disease. The authors concluded that CABG was associated with improved survival at 5 years (5-8 years for those with multi-vessel disease). Unclear inclusion criteria, a limited search and methodological weaknesses mean that the conclusions should be treated with caution.
at a follow-up of 2 to 3 years, 4 to 5 years and 6 to 8 years were extracted as 3-year, 5-year and 8-year end points, respectively. Published survival curves and histograms were digitally scanned and analysed. The outcome data were extracted on an intention-to-treat basis. Summary estimates of effect sizes were calculated for each study.
Methods of synthesis
How were the studies combined? The studies were combined in a meta-analysis, using the random-effects model of DerSimonian and Laird. The weighted percentage risk difference (RD) with 95% confidence intervals (CIs) was calculated and used to estimate the numbers-needed-to-treat (NNT).
How were differences between studies investigated? Statistical heterogeneity was tested using the Q statistic (P<0.1 was considered significant). To explain heterogeneity, the studies were ranked by the event rate in the CABG group, then the characteristics of the studies that contributed most to the heterogeneity in the pooled analysis were examined. Pre-specified subgroup analyses were carried out for single-or multi-vessel disease, the presence or absence of diabetes, and the use or non-use of stents in the initial PTCA strategy.
Results of the review
Thirteen RCTs (7,964 participants) were included.
There was no statistically significant difference in the risk of death or cardiac death between CABG and PTCA at 1 year (11 studies), 3 years (11 studies) or 8 years (4 studies). However, the 5-year follow-up data did show a statistically significant benefit for patients who received CABG: the RD at 5 years was 1.9% (95% CI: 0.33, 3.4, P=0.02) for death (7 studies) and 2.0% (95% CI: 0.29, 3.7, P=0.02) for cardiac death (5 studies). The NNT was about 50 patients. Statistical heterogeneity between the trials was not significant.
The number of subsequent revascularisations required was reduced with CABG, compared with PTCA, at all time points (RD: 24 to 38%, P<0.001). There was statistically significant heterogeneity between the trials for this outcome (P<0.001).
There was no statistically significant effect of either CABG or PTCA on the number of nonfatal MIs.
For the combined outcome (death, MI, revascularisation) the risk of an event was greater in the PTCA treated group at 1, 3 and 5 years (RD: 26 to 31%, P<0.001). Statistical heterogeneity between the trials was not significant. Compared with PTCA, there was a reduction in angina with CABG at 1 and 3 years: the RD was 11% (95% CI: 7.5, 14, P<0.001) at 1 year and 9% (95% CI: 5, 13, P<0.001) at 3 years. There was statistically significant heterogeneity between the trials (P<0.02).
CABG was associated with a reduction in subsequent revascularisations in trials that used stents with PTCA and in trials that did not use stents: the RDs at 3 years were 15% (3 trials; 95% CI: 10, 20, P<0.001) and 34% (7 trials; 95% CI: 28, 40, P<0.001), respectively. There was statistically significant heterogeneity between the trials that did not use stents. No trial directly compared PTCA with and without stents versus CABG.
In the subgroup analyses, CABG provided a survival advantage over PTCA for multi-vessel disease at 5 and 8 years: the RD was 2.3% (95% CI: 0.29, 4.3, P=0.025) at 5 years and 3.4% (95% CI: 0.32, 6.4, P=0.03) at 8 years. At 4 years' follow-up, CABG provided a survival advantage over PTCA in diabetic patients (RD 8.6%, 95% CI: 2.2, 15, P=0.01), but this was not significant at 6.5 years.
